Background: Pediatric gastroenteropancreatic neuroendocrine tumors are exceedingly rare. resulting in most pediatric treatment recommendations being based on data derived from adults. Trametinib is a kinase inhibitor that targets MEK1/2 and has been employed in the treatment of cancers harboring mutations in the Ras pathway. Methods: We utilized an established human pediatric gastroen... https://www.ealisboa.com/top-sale-AR-10-Vert-Monoband-Indep-10m-2-Ringo-quick-deal/
Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors
Internet 3 hours ago pmuiitla9sb0yWeb Directory Categories
Web Directory Search
New Site Listings